Telespa - telemonitoring in AxSpA « minimal impact on disease control « never examine a patient again , never find any pathology outside of joints, remote SpAologists, no longer physicians - easy to train rheumatology nurses to do our jobs @RheumNow #EULAR2024

Telespa - telemonitoring in AxSpA « minimal impact on disease control « never examine a patient again , never find any pathology outside of joints, remote SpAologists, no longer physicians - easy to train rheumatology nurses to do our jobs @RheumNow #EULAR2025

Four phenotypes of chronic back pain suspicious of axial spondyloarthritis (axSpA) in the SPACE cohort. These groups were: They were “axial”, “axSpA with peripheral signs”, “at risk” and “no SpA”. Over a 2 year follow up, Transitions between the four classes over two years were… https://t.co/lF1wtAo46Q https://t.co/BXj1nw0tto

• https://twitter.com/i/web/status/1801958038095421519
• https://twitter.com/synovialjoints/status/1801958038095421519/photo/1

Work ability is impaired in the majority of axSpA patients as measured by the WAI score. 996 patients were included with a mean WAI score of 31.7. Overall, 28%/43% of patients were in poor/moderate work ability, were older, more often obese , had lower education level and… https://t.co/D7oFn31Of5 https://t.co/g79riND9AO

• https://twitter.com/i/web/status/1801955462868316196
• https://twitter.com/synovialjoints/status/1801955462868316196/photo/1

Reassessment of the cut-off values for ASDAS disease activity states in a large, multinational cohort of axSpA patients resulted in cut-offs largely similar to the currently endorsed cut-offs of 1.3, 2.1 and 3.5. Cut-off values between ID and LDA and between LDA and HDA, however,… https://t.co/vECCsmTggW https://t.co/XU7BQBYBdQ

• https://twitter.com/i/web/status/1801950243589644703
• https://twitter.com/synovialjoints/status/1801950243589644703/photo/1

New validated BASDAI cut offs. BASDAI values of <2, <4 and >6 are often applied as cut-offs between remission, low (LDA), high (HDA) and very high (VHDA) disease activity, respectively, although this remains unvalidated. The optimal BASDAI values against external criteria were… https://t.co/5cvWoddHaN https://t.co/oBwYmFsIga

• https://twitter.com/i/web/status/1801947275368804667
• https://twitter.com/synovialjoints/status/1801947275368804667/photo/1

EULAR Abstract Archive POS0894 (2024) SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA Reassuring 15000 pt yrs f/u RA PsA AS https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

• EULAR Abstract Archive